Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Urogenital Regimens



Prostate Regimens


Published

Name Version Date
GU PROS Castration resistant Metastatic - abiraterone and dexamethasone1.0.019/04/2021
GU PROS Castration resistant Metastatic - abiraterone and prEDNISone1.0.002/03/2021
GU PROS Castration resistant Metastatic - abiraterone and prEDNISone [fed state]1.0.002/03/2021
GU PROS Castration resistant Metastatic - apalutamide1.0.018/08/2024
GU PROS Castration resistant Metastatic - cabazitaxel Q3W and prEDNISone2.0.013/08/2023
GU PROS Castration resistant Metastatic - cARBOplatin and DOCEtaxel3.0.013/08/2023
GU PROS Castration resistant Metastatic - DOCEtaxel Q2W and prEDNISone1.0.003/03/2021
GU PROS Castration resistant Metastatic - DOCEtaxel Q3W and prEDNISone1.0.003/03/2021
GU PROS Castration resistant Metastatic - enzalutamide1.0.029/06/2021
GU PROS Castration resistant NON-Metastatic - apalutamide1.0.019/04/2021
GU PROS Castration resistant NON-Metastatic - darolutamide1.0.001/08/2024
GU PROS Castration sensitive Metastatic - abiraterone and prEDNISone1.0.003/03/2021
GU PROS Castration sensitive Metastatic - abiraterone and prEDNISone [fed state]1.0.018/09/2024
GU PROS Castration sensitive Metastatic - apalutamide1.0.019/04/2021
GU PROS Castration sensitive Metastatic - DOCEtaxel Q3W1.0.003/03/2021
GU PROS Castration sensitive Metastatic - DOCEtaxel, abiraterone and prEDNISone1.0.005/09/2024
GU PROS Castration sensitive Metastatic - enzalutamide1.0.001/08/2024
GU PROS Castration sensitive NON-Metastatic - apalutamide1.0.018/08/2024
GU PROS Locally advanced/Metastatic - degarelix1.0.001/08/2024
GU PROS Metastatic - bicalutamide1.0.019/04/2021
GU PROS Metastatic - cyproterone1.0.003/03/2021
GU PROS Metastatic - denosumab1.0.001/08/2024
GU PROS Metastatic - flutamide1.0.019/04/2021
GU PROS Metastatic - goserelin1.0.019/04/2021
GU PROS Metastatic - olaparib1.0.001/08/2024
GU PROS Metastatic - pembrolizumab [flat dose]3.0.017/10/2022
GU PROS Metastatic - peptide receptor radionuclide therapy with lutetium Lu 177 vipivotide tetraxetan1.0.018/08/2024
GU PROS Metastatic - zoledronic acid Q12W1.0.029/06/2021
GU PROS Metastatic - zoledronic acid Q4W1.0.029/06/2021
GU PROS Metastatic - zoledronic acid Q6W1.0.012/05/2022
GU PROS Small cell prostate cancer - cARBOplatin and etoposide1.0.001/08/2024
GU PROS Small cell prostate cancer - cARBOplatin and oral etoposide1.0.001/08/2024

Non-Prostate Regimens



Renal Regimens


Published

Name Version Date
GU Renal cell Adjuvant - pembrolizumab Q3W [flat dosing]1.0.010/12/2024
GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing]1.0.024/08/2023
GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing]1.0.024/08/2023
GU Renal cell Advanced - nivolumab Q2W [flat dosing]1.0.021/08/2023
GU Renal cell Advanced - nivolumab Q4W [flat dosing]1.0.021/08/2023
GU Renal cell Metastatic - aXITinib1.0.021/08/2023
GU Renal cell Metastatic - aXITinib and pembrolizumab Q3W [flat dosing]1.0.021/08/2023
GU Renal cell Metastatic - aXITinib and pembrolizumab Q6W [flat dosing]1.0.021/08/2023
GU Renal cell Metastatic - beVACizumab and erlotinib1.0.028/08/2023
GU Renal cell Metastatic - cABOZANtinib1.0.021/08/2023
GU Renal cell Metastatic - cABOZANtinib and nivolumab1.0.024/08/2023
GU Renal cell Metastatic - everolimus1.0.021/08/2023
GU Renal cell Metastatic - leNVAtinib and everolimus1.0.024/08/2023
GU Renal cell Metastatic - leNVAtinib and everolimus2.0.010/12/2024
GU Renal cell Metastatic - leNVAtinib and pembrolizumab Q3W [flat dosing]1.0.021/08/2023
GU Renal cell Metastatic - pAZOPanib1.0.021/08/2023
GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing]1.0.021/08/2023
GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] and ipilimumab1.0.024/08/2023
GU Renal cell Metastatic - pembrolizumab Q6W [flat dosing]1.0.021/08/2023
GU Renal cell Metastatic - sUNITinib1.0.021/08/2023

Discontinued Regimens

Name Version Published date
GU Renal cell Metastatic - aXITinib and avelumab [flat dose]1.0.206/12/2024